Javascript must be enabled to continue!
Outcomes of inpatients with and without sickle cell disease after high‐volume surgical procedures
View through CrossRef
AbstractIn this study, we examined differences in inpatient costs, length of stay, and in‐hospital mortality between hospitalizations for patients with and without sickle cell disease (SCD) undergoing high‐volume surgical procedures. We used Clinical Classification Software (CCS) codes to identify discharges in the 2002–2005 Nationwide Inpatient Sample of the Healthcare Cost and Utilization Project for patients who had undergone either cholecystectomy or hip replacement. We limited the non‐SCD cohort to hospitals where patients with SCD had undergone the same procedure. We compared inpatient outcomes using summary statistics and generalized linear regression analysis to adjust for patient, hospital, and procedural characteristics. Overall, the median age of surgical patients with SCD was more than three decades less than the median age of patients without SCD undergoing the same procedure. In recognition of the age disparity, we limited the analyses to patients aged 18 to 64 years. Nonetheless, patients with SCD undergoing cholecystectomy or hip replacement were 12.1 and 14.4 years younger, had inpatient stays that were 73% and 82% longer, and incurred costs that were 46% and 40% higher per discharge than patients without SCD, respectively. Inpatient mortality for these procedures was low, ∼0.6% for cholecystectomy and 0.2% for hip replacement and did not differ significantly between patients with and without SCD. Multivariable regression analyses revealed that higher inpatient costs among patients with SCD were primarily attributable to longer hospital stays. Patients with SCD who underwent cholecystectomy or hip replacement required more health care resources than patients without SCD. Am. J. Hematol. 2009. © 2009 Wiley‐Liss, Inc.
Title: Outcomes of inpatients with and without sickle cell disease after high‐volume surgical procedures
Description:
AbstractIn this study, we examined differences in inpatient costs, length of stay, and in‐hospital mortality between hospitalizations for patients with and without sickle cell disease (SCD) undergoing high‐volume surgical procedures.
We used Clinical Classification Software (CCS) codes to identify discharges in the 2002–2005 Nationwide Inpatient Sample of the Healthcare Cost and Utilization Project for patients who had undergone either cholecystectomy or hip replacement.
We limited the non‐SCD cohort to hospitals where patients with SCD had undergone the same procedure.
We compared inpatient outcomes using summary statistics and generalized linear regression analysis to adjust for patient, hospital, and procedural characteristics.
Overall, the median age of surgical patients with SCD was more than three decades less than the median age of patients without SCD undergoing the same procedure.
In recognition of the age disparity, we limited the analyses to patients aged 18 to 64 years.
Nonetheless, patients with SCD undergoing cholecystectomy or hip replacement were 12.
1 and 14.
4 years younger, had inpatient stays that were 73% and 82% longer, and incurred costs that were 46% and 40% higher per discharge than patients without SCD, respectively.
Inpatient mortality for these procedures was low, ∼0.
6% for cholecystectomy and 0.
2% for hip replacement and did not differ significantly between patients with and without SCD.
Multivariable regression analyses revealed that higher inpatient costs among patients with SCD were primarily attributable to longer hospital stays.
Patients with SCD who underwent cholecystectomy or hip replacement required more health care resources than patients without SCD.
Am.
J.
Hematol.
2009.
© 2009 Wiley‐Liss, Inc.
Related Results
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Abstarct
Introduction
Isolated brain hydatid disease (BHD) is an extremely rare form of echinococcosis. A prompt and timely diagnosis is a crucial step in disease management. This ...
Adverse pregnancy, fetal and neonatal outcomes in women with sickle cell disease in a Middle Eastern country
Adverse pregnancy, fetal and neonatal outcomes in women with sickle cell disease in a Middle Eastern country
Background: Sickle cell disease in pregnancy is associated with high maternal and fetal mortality. However, studies reporting pregnancy, fetal, and neonatal outcomes in women with ...
Selected Testing of Newborns for Sickle Cell Disease
Selected Testing of Newborns for Sickle Cell Disease
There are two main reasons for sickle cell testing: the early detection of those with sickle cell disease and the detection of the carrier state, sickle cell trait. The mortality o...
Exchange Transfusion In Adult Patients With Sickle Cell Disease With Refractory Vaso-Occlusive Crises
Exchange Transfusion In Adult Patients With Sickle Cell Disease With Refractory Vaso-Occlusive Crises
Sickle cell disease occurs in 1/500 African-American births. Pain is one of the most common complications of sickle cell disease and is associated with depression, anxiety, decreas...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Intermittent Fasting in Sickle Cell Disease: Case series and Review of Literature
Intermittent Fasting in Sickle Cell Disease: Case series and Review of Literature
Abstract
Presentation Date: 6/8/2024
Presentation Start Time: 6:00:00 PM
...
Sickle Cell Disease and Uterine Fibroids: Evaluation of the Prevalence of Fibroids across Sickle Cell Genotypes
Sickle Cell Disease and Uterine Fibroids: Evaluation of the Prevalence of Fibroids across Sickle Cell Genotypes
ABSTRACT
Introduction
Uterine fibroids are known to affect >80% of premenopausal American women of African descent, and sick...
MARS-seq2.0: an experimental and analytical pipeline for indexed sorting combined with single-cell RNA sequencing v1
MARS-seq2.0: an experimental and analytical pipeline for indexed sorting combined with single-cell RNA sequencing v1
Human tissues comprise trillions of cells that populate a complex space of molecular phenotypes and functions and that vary in abundance by 4–9 orders of magnitude. Relying solely ...

